Two Sigma Advisers
INBX

Two Sigma Advisers’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Two Sigma Advisers’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-282,000
Closed -$9.86M – 2758
2024
Q1 		$9.86M Buy
282,000
+71,200
+34% +$2.6M 0.02% 544
2023
Q4 		$8.01M Sell
210,800
-99,400
-32% -$2.13M 0.02% 621
2023
Q3 		$5.69M Buy
310,200
+17,200
+6% +$360K 0.01% 673
2023
Q2 		$7.61M Buy
293,000
+19,100
+7% +$446K 0.02% 591
2023
Q1 		$5.17M Buy
273,900
+67,100
+32% +$1.56M 0.01% 793
2022
Q4 		$5.1M Buy
206,800
+57,000
+38% +$1.68M 0.01% 775
2022
Q3 		$2.69M Buy
149,800
+105,600
+239% +$1.9M 0.01% 1025
2022
Q2 		$502K Buy
44,200
+27,600
+166% +$406K ﹤0.01% 1922
2022
Q1 		$370K Buy
+16,600
New +$424K ﹤0.01% 2137
2021
Q2 		– Sell
-10,500
Closed -$211K – 2848
2021
Q1 		$211K Buy
+10,500
New +$307K ﹤0.01% 2347

Other funds holding INBX

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Advisers's INBX Position: Q2 2024 in Review

Two Sigma Advisers sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 282,000 shares — an estimated $9.86M sold.

Two Sigma Advisers first reported a position in INBX in Q1 2021 and held it in 10 quarters. The position peaked at $9.86M in Q1 2024. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

  • Two Sigma Advisers reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
  • Two Sigma Advisers sold 282,000 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $9.86M.
  • Two Sigma Advisers first reported a position in Inhibrx, Inc. Common Stock in Q1 2021 and held it in 10 quarters.
  • Two Sigma Advisers's Inhibrx, Inc. Common Stock position peaked at $9.86M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Two Sigma Advisers's 13F filing for Q2 2024, filed 14 Aug 2024.